Humacyte
HUMA
162 hedge funds and large institutions have $213M invested in Humacyte in 2024 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 53 increasing their positions, 38 reducing their positions, and 25 closing their positions.
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
39% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 38
13% more funds holding
Funds holding: 143 → 162 (+19)
9% more capital invested
Capital invested by funds: $195M → $213M (+$18.1M)
2.78% more ownership
Funds ownership: 29.94% → 32.72% (+2.8%)
44% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $7.9M
Top Buyers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$9.9M |
| 2 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$6.33M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.64M |
| 4 |
BHCM
Brevan Howard Capital Management
St. Helier,
Jersey
|
+$4.19M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.69M |
Top Sellers
| 1 |
Voloridge Investment Management
Jupiter,
Florida
|
-$3.76M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.91M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.62M |
| 4 |
Millennium Management
New York
|
-$1.73M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$1.16M |
HUMA Hedge Fund Activity: Q4 2024 in Review
162 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q4 2024, worth a combined $213M — up 9.3% from $195M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new HUMA positions and 25 closed out — a net gain of 21 holders — while 53 added to existing stakes and 38 trimmed.
The largest buyer was Woodline Partners, adding an estimated $9.9M. The largest seller was Voloridge Investment Management, cutting an estimated $3.76M.
- 162 institutional investors held Humacyte (HUMA) as of Q4 2024, up from 143 in Q3 2024.
- Funds reported $213M of Humacyte stock for Q4 2024, up 9.3% quarter-over-quarter.
- 46 funds opened new Humacyte positions in Q4 2024 and 25 closed out, a net change of +21 holders.
- The largest Humacyte buyer in Q4 2024 was Woodline Partners, an estimated $9.9M added.
- The largest Humacyte seller in Q4 2024 was Voloridge Investment Management, an estimated $3.76M sold.
Based on aggregated 13F filings for Q4 2024.